Abstract
1. Trans-diclofurime has been shown to be a potent group II calcium antagonist in in vitro and in vivo test systems. In contrast to the dihydropyridines, group II calcium antagonists have a reduced propensity to cause reflex tachycardia due to well-balanced inhibitory effects in smooth muscle and heart. Since effects on autonomic reflexes are more reliably assessed in conscious animals, the cardiovascular effects of trans-diclofurime have been examined and compared to those of nifedipine, verapamil and diltiazem in the conscious spontaneously hypertensive rat (SHR). 2. Each SHR had an indwelling catheter in the femoral artery to record mean arterial pressure (MAP) and heart rate (HR) and a cannula in the femoral vein for drug infusion over 1 min. 3. Nifedipine (0.1-3.0 mumol kg-1 i.v.) caused dose-related falls in MAP accompanied by dose-related increases in HR. Trans-diclofurime and verapamil (0.3-3.0 mumol kg-1 i.v.) also caused dose-related decreases in MAP, but significant tachycardia was only seen at 1.0 and 3.0 mumol kg-1. Trans-diclofurime (0.3 mumol kg-1) induced a significant fall in HR. Diltiazem (1.0-10.0 mumol kg-1 i.v.) induced dose-related falls in MAP, significant bradycardia was evident with 1.0 mumol kg-1 and tachycardia with 10 mumol kg-1. Trans-diclofurime and diltiazem induced less tachycardia than nifedipine and verapamil for equivalent falls in MAP. 4. These results suggest that trans-diclofurime is a potent antihypertensive agent in conscious SHR and, like diltiazem, the hypotensive effects are associated with less tachycardia than is usually apparent with calcium antagonists such as nifedipine or verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boles R. G., Yamamura H. I., Schoemaker H., Roeske W. R. Temperature-dependent modulation of [3H]nitrendipine binding by the calcium channel antagonists verapamil and diltiazem in rat brain synaptosomes. J Pharmacol Exp Ther. 1984 May;229(2):333–339. [PubMed] [Google Scholar]
- Bolger G. T., Gengo P., Klockowski R., Luchowski E., Siegel H., Janis R. A., Triggle A. M., Triggle D. J. Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle. J Pharmacol Exp Ther. 1983 May;225(2):291–309. [PubMed] [Google Scholar]
- Godfraind T., Wibo M. Subcellular localization of [3H]-nitrendipine binding sites in guinea-pig ileal smooth muscle. Br J Pharmacol. 1985 Jun;85(2):335–340. doi: 10.1111/j.1476-5381.1985.tb08866.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gross R., Kirchheim H., von Olshausen K. Effects of nifedipine on coronary and systemic hemodynamics in the conscious dog. Arzneimittelforschung. 1979;29(9):1361–1368. [PubMed] [Google Scholar]
- Landry Y., Amellal M., Ruckstuhl M. Can calmodulin inhibitors be used to probe calmodulin effects? Biochem Pharmacol. 1981 Jul 15;30(14):2031–2032. doi: 10.1016/0006-2952(81)90217-3. [DOI] [PubMed] [Google Scholar]
- Mir A. K., Spedding M. Calcium antagonist properties of diclofurime isomers. II. Molecular aspects: allosteric interactions with dihydropyridine recognition sites. J Cardiovasc Pharmacol. 1987 Apr;9(4):469–477. doi: 10.1097/00005344-198704000-00012. [DOI] [PubMed] [Google Scholar]
- Mitchell L. B., Schroeder J. S., Mason J. W. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol. 1982 Feb 18;49(3):629–635. doi: 10.1016/s0002-9149(82)80022-2. [DOI] [PubMed] [Google Scholar]
- Nakaya H., Schwartz A., Millard R. W. Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs. Diltiazem, verapamil, and nifedipine compared. Circ Res. 1983 Mar;52(3):302–311. doi: 10.1161/01.res.52.3.302. [DOI] [PubMed] [Google Scholar]
- Rowland E., Evans T., Krikler D. Effect of nifedipine on atrioventricular conduction as compared with verapamil. Intracardiac electrophysiological study. Br Heart J. 1979 Aug;42(2):124–127. doi: 10.1136/hrt.42.2.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schoemaker H., Hicks P. E., Langer S. Z. Calcium channel receptor binding studies for diltiazem and its major metabolites: functional correlation to inhibition of portal vein myogenic activity. J Cardiovasc Pharmacol. 1987 Feb;9(2):173–180. doi: 10.1097/00005344-198702000-00008. [DOI] [PubMed] [Google Scholar]
- Spedding M. Activators and inactivators of Ca++ channels: new perspectives. J Pharmacol. 1985 Oct-Dec;16(4):319–343. [PubMed] [Google Scholar]
- Spedding M. Differences between the effects of calcium antagonists in the pithed rat preparation. J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):973–979. doi: 10.1097/00005344-198211000-00015. [DOI] [PubMed] [Google Scholar]
- Spedding M., Gittos M., Mir A. K. Calcium antagonist properties of diclofurime isomers. I. Functional aspects. J Cardiovasc Pharmacol. 1987 Apr;9(4):461–468. doi: 10.1097/00005344-198704000-00011. [DOI] [PubMed] [Google Scholar]
- Subramanian V. B., Bowles M. J., Khurmi N. S., Davies A. B., Raftery E. B. Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina. Am J Cardiol. 1982 Oct;50(4):696–703. doi: 10.1016/0002-9149(82)91221-8. [DOI] [PubMed] [Google Scholar]
- Vincenzi M., Allegri P., Gabaldo S., Maiolino P., Ometto R. Hemodynamic effects caused by i.v. administration of verapamil in healthy subjects. Arzneimittelforschung. 1976;26(6):1221–1223. [PubMed] [Google Scholar]
- Walsh R. A., Badke F. R., O'Rourke R. A. Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs. Am Heart J. 1981 Sep;102(3 Pt 1):341–350. doi: 10.1016/0002-8703(81)90307-0. [DOI] [PubMed] [Google Scholar]